Nabil Seidah

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Nabil G. Seidah, CM OQ FRSC (born 1949) is a Canadian Québécois scientist. Born in Egypt, he was educated at Cairo University, and subsequently at Georgetown University where he obtained his Ph.D in 1973.[1][2] He emigrated to Canada and has been working at the Clinical Research Institute of Montreal (IRCM) since 1974.[1] He is the director of the laboratory of Biochemical Neuroendocrinology.[1] Dr. Seidah discovered and cloned seven (PC1, PC2, PC4, PC5, PC7, SKI-1 and PCSK9) of the nine known enzymes belonging to the convertase family. During this period, he also greatly contributed to demonstrating that the proteolysis by the proprotein convertases is a wide mechanism that also concerns “non-neuropeptide” proteins such as growth factors, α-integrins, receptors, enzymes, membrane-bound transcription factors, and bacterial and viral proteins. Recently, he showed that point mutations in the PCSK9 gene cause dominant familial hypercholesterolemia, likely because of a gain of function related to the ability of PCSK9 to enhance the degradation of cell surface receptors, such as the low-density lipoprotein receptor.



  1. ^ a b c d e "Nabil G. Seidah". International Consortium on Anti-Virals. Retrieved 26 December 2010. 
  2. ^ a b "Nabil G. Seidah, FRSC". Royal Society of Canada. Retrieved 26 December 2010. 
  3. ^ a b "Director's biography". Clinical Research Institute of Montreal. Retrieved 26 December 2010. 
  4. ^ "Nabil G. Seidah, C.M., O.Q., Ph.D.". Governor General of Canada. Retrieved 26 December 2010.